Outcomes
death
TUMOR PROGRESSION
The primary endpoint was progression‐free survival (PFS), which was defined as the time from the day nivolumab was initiated until objective tumor progression or death. Secondary endpoints were the objective response rate (ORR) and overall survival (OS), which were also calculated from the initiation of nivolumab. The safety profile was assessed during the study period after the administration of nivolumab. Exploratory objectives included the assessment of blood TMB, which could affect the treatment response of this therapy.